Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Aspirin
Drug: REGN9933
Drug: REGN7508
Drug: Rivaroxaban

First Posted Date: 2024-06-05

Last Posted Date: 2025-06-29

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 224

Registration Number: NCT06444178

Locations: 🇬🇧
Fortrea Clinical Development, Leeds, United Kingdom

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Phase 2

Recruiting

Conditions: Non-transfusion Dependent Beta-thalassemia (NTDT)

Interventions: Drug: REGN7999
Drug: Placebo

First Posted Date: 2024-05-20

Last Posted Date: 2025-05-29

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT06421636

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇹🇭
Phramongkutklao Hospital, Bangkok, Thailand
🇬🇪
K Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia

and more 18 locations

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Phase 1

Recruiting

Conditions: Clear-Cell Renal-Cell Carcinoma (ccRCC)
Advanced Solid Tumors
Melanoma

Interventions: Drug: REGN10597

First Posted Date: 2024-05-14

Last Posted Date: 2025-06-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06413680

Locations: 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸
Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Yale School of Medicine, North Haven, Connecticut, United States

and more 8 locations

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Withdrawn

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Wet Age-related Macular Degeneration (AMD)
Diabetic Macular Edema (DME)
Visual Impairment

Interventions: Drug: aflibercept 8 mg

First Posted Date: 2024-05-03

Last Posted Date: 2024-11-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 800

Registration Number: NCT06398080

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Phase 2

Withdrawn

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: cemiplimab
Drug: fianlimab

First Posted Date: 2024-04-25

Last Posted Date: 2024-07-26

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT06384820

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Phase 1

Recruiting

Conditions: Hemophilia B

Interventions: Drug: REGV131
Drug: LNP1265

First Posted Date: 2024-04-23

Last Posted Date: 2025-06-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT06379789

Locations: 🇺🇸
Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 11 locations

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Phase 1

Recruiting

Conditions: Food Allergy

Interventions: Drug: linvoseltamab
Drug: dupilumab

First Posted Date: 2024-04-17

Last Posted Date: 2025-05-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT06369467

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Emory University- Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 4 locations

First in Human (FIH) Study of ALN-SOD in Adult Participants with Amyotrophic Lateral Sclerosis Associated with Mutation in the SOD1 Gene (SOD1-ALS)

Phase 1/2

Not yet recruiting

Conditions: Amyotrophic lateral sclerosis (ALS)

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-11

Lead Sponsor: Regeneron Pharmaceuticals Inc.

Target Recruit Count: 13

Registration Number: 2023-510344-20-00

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇩🇪
Universitaet Muenster, Muenster, Germany
🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 1 Im.Prof.Stanislawa Szyszko Slaskiego Uniwersytetu Medycznego W Katowicach, Zabrze, Poland

and more 1 locations

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: Trevogrumab-Part B and Part C
Drug: Matching Placebo-Part A
Drug: Trevogrumab-Part A
Drug: Semaglutide
Drug: Garetosmab
Drug: Matching Placebo-Garetosmab
Drug: Matching Placebo-Trevogrumab

First Posted Date: 2024-03-07

Last Posted Date: 2025-05-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 999

Registration Number: NCT06299098

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸
Foothills Research Center Cct Research, Phoenix, Arizona, United States

and more 58 locations

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Phase 2

Recruiting

Conditions: Venous Thromboembolism

Interventions: Drug: REGN9933
Drug: REGN7508
Drug: Placebo

First Posted Date: 2024-03-07

Last Posted Date: 2025-06-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 195

Registration Number: NCT06299111

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇬🇧
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 12 locations

AI-Powered Research

Premium Access

Regeneron Pharmaceuticals

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

First in Human (FIH) Study of ALN-SOD in Adult Participants with Amyotrophic Lateral Sclerosis Associated with Mutation in the SOD1 Gene (SOD1-ALS)

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)